IPOL

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline, CanSino Biologics Inc.

Conditions

Acellular PertussisDiphtheriaInfections, RotavirusPoliomyelitisTetanus

Phase 1

A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults

CompletedNCT06101173

CanSino Biologics Inc.Poliomyelitis

Start: 2024-01-15End: 2024-09-11Updated: 2024-12-04

Phase 2

Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.

CompletedNCT00729001

GlaxoSmithKlineInfections, Rotavirus

Start: 2000-11-30End: 2002-09-30Updated: 2016-09-16

Phase 3

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

CompletedNCT00148941

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2005-01-06End: 2006-12-04Updated: 2020-02-05

Related Papers

Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, <i>Rotarix</i>™: A retrospective laboratory analysis

Human Vaccines & Immunotherapeutics2016-09-228 citations